Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs, Second Edition is a visually engaging reference detailing the essential basic and clinical science of all approved, effective, and life-prolonging drug therapies in oncology. Now with a greater emphasis on clinical context, application, and management in each chapter, this significantly revised edition provides both early-career and seasoned clinicians with a practical, bench-to-bedside approach and patient-oriented guide. The book provides detailed coverage of the major advances in cancer pharmacology at the forefront of our standards of care for solid tumors and hematologic malignancies, in addition to the basic science that is directly necessary and applicable when at the patient's bedside. Everything from traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents is explored, in addition to a new chapter covering pharmacogenomics. Accompanied by elegant illustrations, each chapter details the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic and molecular properties of the various agents, and their mechanisms of action. The book covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Thoroughly updated to include new FDA-approved treatments and applications, and written by leading experts in cancer pharmacology, this second edition continues to be a "must have" for anyone involved in the basic, translational, or clinical aspects of oncology and hematology, including clinicians, pharmacists, nurses, and trainees. Key Features: Over 150 beautiful illustrations depict structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents Contains more than 160 high-yield hematology and oncology board-style chapter review questions (more than double the previous edition) with descriptive rationales Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work, and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other treatment modalities Thoroughly updated and revised chapters cover all new FDA drug approvals, disease-site indications, clinical applications and management of drug-to-drug interactions, and toxicities Discusses challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments Provides important pharmacotherapy context with clinical pearls in each chapter that help support a patient-oriented, bedside approach Purchase includes access to the ebook for use on most mobile devices or computers
Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland. Judith E. Karp, MD is Professor Emerita of Oncology and Medicine at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, in Baltimore, Maryland.
List of Contributors Preface PART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENT Chapter 1. Anticancer Drug Development: An Introduction by Edward A. Sausville, MD, PhD Chapter 2. Pharmacogenomics by Milly Graveno, PharmD, BCOP Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy, MD, Richard F. Little, MD, and Joshua F. Zeidner, MD Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu, PhD, Matthew D. Thompson, PhD, MPH, Donna Przepiorka, MD, PhD, and Olanrewaju O. Okusanya, Pharm.D., MS PART 2. CLASSICAL CYTOTOXIC AGENTS Chapter 5. Alkylating Agents by Ashkan Emadi, MD, PhD and Edward A. Sausville, MD, PhD Chapter 6. Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases by Ashkan Emadi, MD, PhD and Judith E. Karp, MD Chapter 7. Antimetabolites: Antifolates by Justin Lawson, PharmD, BCOP Chapter 8. Antimitotics by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhD PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS Chapter 9. DNA Repair, Apoptotic Pathways, and CDK Inhibitors by Mira A. Kohorst, MD and Scott H. Kaufmann, MD, PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca, MD and Lukasz P. Gondek, MD, PhD Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai, MD, PhD and Gabriel Ghiaur, MD, PhD PART 4. ORGAN-TARGETED APPROACHES Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu, MD and Ashkan Emadi, MD, PhD Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton, PhD and Katherine H. R. Tkaczuk, MD Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar, PhD, and Arif Hussain, MD Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples, PharmD, BCOP and Sagar Lonial, MD PART 5. IMMUNE-TARGETED STRATEGIES Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic, MD Chapter 17. Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, and Cytokine-Directed Agents by Alison Duffy, PharmD, BCOP and Ciera Bernhardi, PharmD, BCOP Chapter 18. Immunotherapeutics: Checkpoint Inhibitors, Vaccines, Bispecifics, and CAR-T by Mark Yarchoan, MD and Elizabeth Jaffee, MD Index
